Lynparza (olaparib tablets – AstraZeneca) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has metastatic castration-resistant prostate cancer
• Medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR patient has had a bilateral orchiectomy
• Patient has germline or somatic homologous recombination repair (HRR) gene-mutated disease confirmed by an approved test AND patient has been previously treated with at least one androgen receptor-directed therapy

Approval duration

1 year